Schilke Tobin — SEC Form 4 filings
SEC reporting owner CIK 1678984. 12 Form 4 filings on record with FilingPulse; latest filed 2026-09-01.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-02-02 to 2026-09-01. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 2 legs across 2 filings — 16,074 shares, $313,508 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 20.
- Largest priced transaction: sale of 6,713 shares @ $39.67 ($266,305) in Crinetics Pharmaceuticals, Inc., filed 2026-03-04.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Crinetics Pharmaceuticals, Inc. (CRNX) | Chief Financial & Infra. Ofcr. | 5 | — | 1 leg · 6,713 sh · $266,305 | 9 |
| Revance Therapeutics, Inc. (RVNC) | CFO | 7 | — | 1 leg · 9,361 sh · $47,204 | 11 |
Form 4 filings — Schilke Tobin
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-01 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Disposition to issuer (D): 7,956 @ $85 · Disposition to issuer (D): 71,471 @ $85 · Disposition to issuer (D): 80,000 (derivative) @ $51.25 · Disposition to issuer (D): 50,000 (derivative) @ $41.21 | EDGAR |
| 2026-08-24 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Grant/award (A): 471 @ $0 | EDGAR |
| 2026-03-04 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Sale (S): 6,713 @ $39.67 | EDGAR |
| 2026-02-25 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Grant/award (A): 32,000 @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-03-11 | 4 | Crinetics Pharmaceuticals, Inc. (CRNX) | Grant/award (A): 52,000 @ $0 · Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | Revance Therapeutics, Inc. (RVNC) | Code (U): 97,999 @ $3.65 · Disposition to issuer (D): 103,555 · Grant/award (A): 20,883 @ $0 · Disposition to issuer (D): 20,883 | EDGAR |
| 2025-02-05 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 6,888 @ $0 | EDGAR |
| 2025-01-03 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 1,000 @ $2.18 | EDGAR |
| 2024-07-02 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 1,000 @ $2.18 | EDGAR |
| 2024-03-19 | 4 | Revance Therapeutics, Inc. (RVNC) | Tax withholding (F): 3,822 @ $5.30 · Sale (S): 9,361 @ $5.04 | EDGAR |
| 2024-03-04 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 17,447 @ $0 | EDGAR |
| 2024-02-02 | 4 | Revance Therapeutics, Inc. (RVNC) | Grant/award (A): 96,667 @ $0 · Grant/award (A): 145,001 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1678984 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →